Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4415-4421

  Baldini, Editta ^a   Camerini, Andrea ^a,b   Sgambato, Alessandro ^b   Prochilo, Tiziana ^a   Capodanno, Alessandra ^a   Pasqualetti, Francesco ^a   Orlandini, Cinzia ^a   Resta, Letizia ^c   Bevilacqua, Generoso ^a   Collecchi, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Breast cancer; Cyclin A; Disease free survival; E2F1; Ki67

Indexed keywords

ANTHRACYCLINE; CYCLIN A; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GESTAGEN; KI 67 ANTIGEN; METHOTREXATE; TAMOXIFEN; TRANSCRIPTION FACTOR E2F1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

BREAST NEOPLASMS; CYCLIN A; DISEASE-FREE SURVIVAL; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

EID: 33845960448     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H and Margolese R: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer (Phila) 52: 1551-1557, 1983.
2. Loprinzi CL and Thomè SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19: 972-979, 2001.
3. Fisher ER, Redmond C and Fisher B: Prognostic factors in NSABP studies of women with node-negative breast cancer. J Nat Cancer Inst Monogr 11: 151-158, 1992.
4. Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971, 1992.
5. Woo RA and Poon RY: Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle 2: 316-324, 2003.
6. Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326, 2002.
7. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI and Weinberg RA: Regulation of retinoblastoma protein functions by ectopic expression of humans cyclins. Cell 70: 993-1006, 1992.
8. Rosenberg AR, Zindy F, Le Deist F, Mouly H, Metezeau P, Brechot and Lamas E: Overexpression of human cyclin A advances entry into S phase. Oncogene 10: 1501-1509, 1995.
9. Schulze A, Zerfass-Thome K, Berges J, Middendorp S, Jansen-Durr P and Henglein B: Anchorage-dependent transcription of the cyclin A gene. Mol Cell Biol 16: 4652-4658, 1995.
10. Zerfass-Thome K, Spitkosky D, Schulze A, Joswig S, Henglein B and Jansen-Durr P: Adenovirus E1A activates cyclin A gene transcription in the absence of growth factors through interaction with p107. J Virol 70: 2637-2642, 1996.
11. Sgambato A, Flamini G, Cittadini A and Weinstein IB: Abnormalities in cell cycle control in cancer and their clinical implications. Tumori 84: 421-433, 1998.
12. Nozoe T, Inutsuka S, Honda M, Elaki T and Korenaga D: Clinicopathologic significance of cyclin A expression in colorectal carcinoma. J Exp Clin Cancer Res 23: 127-133, 2004.
13. Ito Y, Takeda T, Wasaka K, Tsujimoto M, Okada M and Matsuura N: Expression of the G2-M modulators in pancreatic adenocarcinoma. Pancreatology 2: 138-145, 2002.
14. Dong Y, Sui L, Watanabe Y, Sugimoto K and Tokuda M: Aberrant expression of cyclin A in laryngeal squamous cell carcinoma. Anticancer Res 22: 83-89, 2002.
15. Michalides R, Van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J and Van Diest P: Cyclin A is a prognostic indicator in early stage breast cancer with or without tamoxifen treatment. Br J Cancer 86: 402-408, 2002.
16. Saarilahti K, Kajanti M, Kuori M, Aaltonen LM, Franssila K and Joensuu M: Cyclin A and Ki67 expression as predictors for locoregional recurrence and outcome in laryngeal cancer patients treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 57: 986-995, 2003.
17. Holm C, Ora I, Brunhoff C, Anagnostaki L, Landberg G and Persson JL: Cyclin A1 expression and association with disease characteristics in childhood acute lymphoblastic leukaemia. Leuk Res 30: 254-261, 2006.
18. Hiebert SW, Packham G, Strom DK, Haffner R, Oren H, Zambretti G and Cleveland JL: E2F1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 15: 3082-3089, 1995.
19. Singh P, Wong Sh and Hong W: Overexpression of E2F1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 13: 3329-3338, 1994.
20. Xu G, Livingston DM and Krek W: Multiple members of the E2F transcription factor family are the products of oncogenes. PNAS 92: 1357-1361, 1995.
21. Pan H, Yin C, Dyson NJ, Harlow E, Yarasaky L and Van Dyke T: Key roles for E2F1 in signalling p53-dependent apoptosis and cell division within developing tumors. Molec Cell 2: 283-292, 1998.
22. Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges S, Helin K, Jansen-Durr P and Henglein B: Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. PNAS 21: 11264-11268, 1995.
23. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH and Greenberg ME: E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85: 549-561, 1996.
24. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E and Dyson NJ: Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-548, 1996.
25. Bloom HJG and Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
26. Collecchi P, Passoni A, Rocchetta M, Gnesi E, Baldini E and Bevilacqua G: Cyclin-D1 expression in node-positive (N+) and node-negative (N-) infiltrating human mammary carcinomas. Int J Cancer 84: 139-144, 1999.
27. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J and Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-39 detect proliferating cells in microwave processed formalin-fixed sections. J Pathol 168: 357-363, 1992.
28. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD and Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle maintaining proteins. J Cell Biol 123: 513-522, 1993.
29. MacCallum DE and Hall PA: The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol 190: 537-544, 2000.
30. Plaat B, Kole A, Mastik M, Hoekstra H, Molenaar W and Waalburg W: Protein synthesis rate measured with L-[1-11C] tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med 26: 328-332, 1999.
31. Bridger JM, Kill IR and Lichter P: Association of pKi-67 with satellite DNA of the human genome in early G1 cells. Chromosome Res 6: 13-24, 1998.
32. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
33. Fan J and Bertino JR: Functional roles of E2F in cell cycle regulation. Oncogene 14: 1191-1200, 1997.
34. Ohtani K, DeGregori J and Nevis JR: Regulation of the cyclin E gene transcription factor E2F1. PNAS 92: 12146-12150, 1995.
35. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP, Nikiteas N, Pazaiti A, Kittas C, Bastounis E and Gorgoulis VG: E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res 24: 3041-3047, 2004.
36. Darbinian N, White MK, Gallia GL, Amini S, Rappaport J and Khalili K: Interaction between the pura and E2F-1 transcription factors. Anticancer Res 24: 2585-2594, 2004.